[an error occurred while processing this directive] | [an error occurred while processing this directive]
Clinical efficacy of HDR brachytherapy with concomitant complementary IMRT boost for bulky uterine cervical cancer
Lu Shun, Fan Zixuan, Sun Chang, Tan Mingyu, Zhang Hanyi, Feng Mei, Yin Jun, Yin Gang, Li Jie, Lang Jinyi
Department of Radiotherapy,Sichuan Cancer Center/Sichuan Cancer Hospital& Institute,School of Medicine,University of Electronic Science and Technology of China,Chengdu 610041,China
AbstractObjective To investigate the clinical outcomes of patients with locally advanced uterine cervical cancer (UCC) treated by 3-dimensional high dose rate-intracavitary brachytherapy (3D HDR-ICBT) combined with complementary applicator-guided external beam radiotherapy (EBRT). Methods A total of 120 patients pathologically diagnosed with locally advanced UCC (tumors with a maximum diameter≥6 cm or≥5 cm complicated with eccentric tumor growth) treated with concurrent chemoradiotherapy (CCRT) from June 2010 to June 2015 were recruited. Five fractions of 3D HDR-ICBT combined with complementary applicator-guided external beam radiotherapy were performed. The prescribed dose for HR-CTV and IR-CTV was 7 Gy(D90) and 5-6 Gy(D90). The rectum, sigmoid colon, bladder and adjacent small intestine were delineated as the organs at risk. Intensity-modulated radiation therapy (IMRT) was used for EBRT (45 Gy/25f) combined with cisplatin-based chemotherapy every three weeks (75 mg/m2). Results The median follow-up time was 46 months (14-96 months). The 5-year local control rate (LCR),disease-free survival (DFS),and overall survival (OS) were 92.8%,76.6% and 81.0%,respectively. The incidence rate of grade I-Ⅱ genitourinary and gastrointestinal acute toxicities were 57.8% and 14.6%, whereas 8.1% and 2.9% for grade Ⅲ toxicities. The incidence rate of later grade Ⅰ-Ⅱ genitourinary and gastrointestinal toxicities were 8.4% and 5.3%, and 0.97% and 1.3% for grade Ⅲ late toxicities. Conclusions The combination of HDR-ICBT with an applicator-guided IMRT (ICBT+IMRT) yields low incidence of severe adverse events, relatively high LC and OS rate for locally advanced UCC. It is an efficacious comprehensive treatment of locally advanced bulky UCC.
Corresponding Authors:
Lang Jinyi, Email:langjy610@163.com
Cite this article:
Lu Shun,Fan Zixuan,Sun Chang et al. Clinical efficacy of HDR brachytherapy with concomitant complementary IMRT boost for bulky uterine cervical cancer[J]. Chinese Journal of Radiation Oncology, 2019, 28(7): 522-526.
Lu Shun,Fan Zixuan,Sun Chang et al. Clinical efficacy of HDR brachytherapy with concomitant complementary IMRT boost for bulky uterine cervical cancer[J]. Chinese Journal of Radiation Oncology, 2019, 28(7): 522-526.
[1]Fitzmaurice C,Akinyemiju TF,Al Lami FH,et al. Global,regional,and national cancer incidence,mortality,years of life lost,years lived with disability,and disability-adjusted life-years for 29 cancer groups,1990 to 2016:a systematic analysis for the global burden of disease study[J]. JAMA Oncol,2018,4(11):1553-1568. DOI:10.1001/jamaoncol.2018.2706. [2]Green J,Kirwan J,Tierney J,et al. Concomitant chemotherapy and radiation therapy for cancer of the uterine cervix[CD]. The cochrane database of systematic reviews:CD002225.2005. [3]Rose PG,Bundy BN,Watkins EB,et al. Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer[J]. New Engl J Med,1999,340(15):1144-1153. DOI:10.1056/NEJM199904153401502. [4]Logsdon MD,Eifel PJ. Figo ⅢB squamous cell carcinoma of the cervix:an analysis of prognostic factors emphasizing the balance between external beam and intracavitary radiation therapy[J]. Int J Radiat Oncol Biol Phys,1999,43(4):763-775. DOI:10.1016/S0360-3016(98)00482-9. [5]Hanks GE,Herring DF,Kramer S. Patterns of care outcome studies. Results of the national practice in cancer of the cervix[J]. Cancer,1983,51(5):959-967. DOI:1016/S0210-0048. [6]Duan J,Kim RY,Elassal S,et al. Conventional high-dose-rate brachytherapy with concomitant complementary IMRT boost:a novel approach for improving cervical tumor dose coverage[J]. Int J Radiat Oncol Biol Phys,2008,71(3):765-771. DOI:10.1016/j.ijrobp.2007.10.064. [7]Yin G,Wang P,Lang J,et al. Dosimetric study for cervix carcinoma treatment using intensity modulated radiation therapy (IMRT) compensation based on 3D intracavitary brachytherapy technique[J]. J Contemp Brachyther, 2016,8(3):221-232. DOI:10.5114/jcb.2016.60590. [8]Hellebust TP,Kirisits C,Berger D,et al. Recommendations from gynaecological (GYN) GEC-ESTRO working group:considerations and pitfalls in commissioning and applicator reconstruction in 3D image-based treatment planning of cervix cancer brachytherapy[J]. Radiother Oncol, 2010,96(2):153-160. DOI:10.1016/j.radonc.2010.06.004. [9]Cox JD,Stetz J,Pajak TF. Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC)[J]. Int J Radiat Oncol Biol Phys,1995,31(5):1341-1346. DOI:10.1016/0360-3016(95)00060-C. [10]Vordermark D. Radiotherapy of Cervical Cancer. Oncol Res Treat,2016,39(9):516-520. DOI:10.1159/000448902. [11]Barillot I,Horiot JC,Maingon P,et al. Impact on treatment outcome and late effects of customized treatment planning in cervix carcinomas:baseline results to compare new strategies[J]. Int J Radiat Oncol Biol Phys,2000,48(1):189-200. DOI:https://doi.org/10.1016/S0360-3016(00)00556-3. [12]Guerrero M,Li XA,Ma L,et al. Simultaneous integrated intensity-modulated radiotherapy boost for locally advanced gynecological cancer:radiobiological and dosimetric considerations[J]. Int J Radiat Oncol Biol Phys,2005,62(3):933-999. DOI:10.1016/j.ijrobp.2004.11.040. [13]Aydogan B,Mundt AJ,Smith BD,et al. A dosimetric analysis of intensity-modulated radiation therapy (IMRT) as an alternative to adjuvant high-dose-rate (HDR) brachytherapy in early endometrial cancer patients[J]. Int J Radiat Oncol Biol Phys,2006,65(2):266-273. DOI:10.1016/j.ijrobp.2005.12.049. [14]Dimopoulos JC,Pötter R,Lang S,et al. Dose-effect relationship for local control of cervical cancer by magnetic resonance image-guided brachytherapy[J]. Radiother Oncol,2009,93(2):311-315. DOI:10.1016/j.radonc.2009.07.001. [15]Fallon J,Park SJ,Yang L,et al. Long term results from a prospective database on high dose rate (HDR) interstitial brachytherapy for primary cervical carcinoma[J]. Gynecol Oncol, 2016,pii:S0090-8258(16)31496-2. DOI:10.1016/j.ygyno.2016.10.020. [16]Pötter R,Georg P,Dimopoulos JC,et al. Clinical outcome of protocol based image (MRI) guided adaptive brachytherapy combined with 3D conformal radiotherapy with or without chemotherapy in patients with locally advanced cervical cancer[J]. Radiother Oncol,2011,100(1):116-123. DOI:10.1016/j.radonc.2011.07.012. [17]Lindegaard JC,Fokdal LU,Nielsen SK,et al. MRI-guided adaptive radiotherapy in locally advanced cervical cancer from a Nordic perspective[J]. Acta Oncol,2013,52(7):1510-1519. DOI:10.3109/0284186X.2013.818253. [18]Pinn-Bingham M,Puthawala AA,Syed AM,et al. Outcomes of high-dose-rate interstitial brachytherapy in the treatment of locally advanced cervical cancer:long-term results[J]. Int J Radiat Oncol Biol Phys,2013,85(3):714-20. DOI:10.1016/j.ijrobp.2012.05.033.
2019, Vol. 28 
